UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 5)*
INDEVUS PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $.001
--------------------------------------------------------------------------------
(Title of Class of Securities)
454072109
--------------------------------------------------------------------------------
(CUSIP Number)
NOVEMBER 27, 2007
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS
FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB
CONTROL NUMBER.
SEC 1745 (12-02)
--------------------------------------- --------------------------------------- --------------------------------------
CUSIP No. 454072109 13G/A Page 2 of 7 Pages
--------------------------------------- --------------------------------------- --------------------------------------
--------- ------------------------------------------------------------------------------------------------------------
1.
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
JOSEPH EDELMAN
--------- ------------------------------------------------------------------------------------------------------------
--------- ------------------------------------------------------------------------------------------------------------
2.
CHECK THE APPROPRIATE BOX IF A GROUP* (a)
(b) |X|
--------- ------------------------------------------------------------------------------------------------------------
--------- ------------------------------------------------------------------------------------------------------------
3. SEC USE ONLY
--------- ------------------------------------------------------------------------------------------------------------
--------- ------------------------------------------------------------------------------------------------------------
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
UNITED STATES OF AMERICA
--------- ------------------------------------------------------------------------------------------------------------
------------------- ----- --------------------------------------------- ----------------------------------------------
NUMBER OF 5.
SHARES SOLE VOTING POWER 3,675,215
------------------- ----- --------------------------------------------- ----------------------------------------------
------------------- ----- --------------------------------------------- ----------------------------------------------
BENEFICIALLY 6.
OWNED BY SHARED VOTING POWER 0
------------------- ----- --------------------------------------------- ----------------------------------------------
------------------- ----- --------------------------------------------- ----------------------------------------------
EACH 7.
REPORTING SOLE DISPOSITIVE POWER 3,675,215
------------------- ----- --------------------------------------------- ----------------------------------------------
------------------- ----- --------------------------------------------- ----------------------------------------------
PERSON WITH: 8.
SHARED DISPOSTIVE POWER 0
------------------- ----- --------------------------------------------- ----------------------------------------------
--------- ---------------------------------------------------------------------------- -------------------------------
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,675,215
--------- ---------------------------------------------------------------------------- -------------------------------
--------- ------------------------------------------------------------------------------------------------------------
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
--------- ------------------------------------------------------------------------------------------------------------
--------- ---------------------------------------------------------------------------- -------------------------------
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.62 %
--------- ---------------------------------------------------------------------------- -------------------------------
--------- ---------------------------------------------------------------------------- -------------------------------
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN
--------- ---------------------------------------------------------------------------- -------------------------------
---------------------------------------- -------------------------------------- ----------------------------------------
CUSIP No. 454072109 13G/A Page 3 of 7 Pages
---------------------------------------- -------------------------------------- ----------------------------------------
ITEM 1.
(a) Name of Issuer: INDEVUS PHARMACEUTICALS, INC.
(b) Address of Issuer's Principal Executive Offices: 33 HAYDEN AVENUE
LEXINGTON, MA 02421
ITEM 2.
THIS SCHEDULE IS BEING FILED WITH RESPECT TO SHARES OF COMMON STOCK OF THE
(a) Name of Person Filing: ISSUER WHICH ARE BENEFICIALLY OWNED BY JOSEPH EDELMAN. SEE ITEM 4 BELOW.
PERCEPTIVE ADVISORS LLC
499 PARK AVENUE, 25TH FLOOR
(b) Address of Principal Business Office or, if none, Residence: NEW YORK, NY 10022
(c) Citizenship: EACH OF THE REPORTING PERSON IS A UNITED STATES CITIZEN
(d) Title of Class of Securities: COMMON STOCK, PAR VALUE $.001
(e) CUSIP Number: 454072109
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS.240.13D-1(B) OR
240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C
80a-8).
(e) [ ] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with ss. 240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12
U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
---------------------------------------- -------------------------------------- ----------------------------------------
CUSIP No. 454072109 13G/A Page 4 of 7 Pages
---------------------------------------- -------------------------------------- ----------------------------------------
OWNERSHIP.
ITEM 4.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
Mr. Edelman beneficially owns: 3,675,215
shares (comprised of (i) 490,450 shares and
notes convertible into 3,046,875 shares held
by Perceptive Life Sciences Master Fund Ltd.
("Master Fund"), a Cayman Islands company of
which the investment manager is Perceptive
Advisors LLC, a Delaware limited liability
(a) Amount beneficially owned: company of which Mr. Edelman is the managing
member, (ii) notes convertible into 300,480
shares held personally by Mr. Edelman and
(iii) 410 shares held in an account of
First New York Trading, LLC of which Mr.
Edelman has voting and dispositive power.
The beneficial ownership of 4.62% is based on
the sum of (i) 76,192,485 shares issued and
outstanding as of August 6, 2007 as reported on
(b) Percent of class: the Issuer's 10-Q as filed with the SEC on
August 9, 2007, (ii) notes convertible into
3,046,875 shares held by the Master Fund and
(iii) notes convertible into 300,480 shares
held personally by Mr. Edelman.
---------------------------------------- -------------------------------------- --------------------------------------
CUSIP No. 454072109 13G/A Page 5 of 7 Pages
---------------------------------------- -------------------------------------- --------------------------------------
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 3,675,215
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the disposition of: 3,675,215
(iv) Shared power to dispose or to direct the disposition of:
0
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be
the beneficial owner of more than five percent of the class of securities, check the following [X].
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
As referred to in Item 4, other persons have the right to receive and the power
to direct the receipt of dividends from, and the proceeds from the sale of,
certain of the shares reported herein. In that regard Mr. Edelman is the
managing member of Perceptive Advisors LLC, the investment manager of the Master
Fund. Accordingly, the Master Fund has the right to receive and the power to
direct the receipt of, dividends and the proceeds from the sale of the shares
reported herein that are held through the master Fund which shares represent
greater than 5% of the shares outstanding.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON.
See Exhibit A.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
---------------------------------------- -------------------------------------- --------------------------------------
CUSIP No. 454072109 13G/A Page 6 of 7 Pages
---------------------------------------- -------------------------------------- --------------------------------------
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.
ITEM 10. CERTIFICATION
The following certification shall be included if the statement
is filed pursuant to ss.240.13d-1(b):
By signing below I certify that, to the best
of my knowledge and belief, the securities
referred to above were acquired and are held
in the ordinary course of business and were
(a) not acquired and are not held for the purpose
of or with the effect of changing or
influencing the control of the issuer of the
securities and were not acquired and are not
held in connection with or as a participant
in any transaction having that purpose or
effect. [X]
---------------------------------------- -------------------------------------- --------------------------------------
CUSIP No. 454072109 13G/A Page 7 of 7 Pages
---------------------------------------- -------------------------------------- --------------------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
July 14, 2008
-------------
Date
/s/ Joseph Edelman
------------------
Signature
Joseph Edelman
--------------
Name/Title
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is signed
on behalf of a person by his authorized representative other than an executive
officer or general partner of the filing person, evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement, provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. SEE ss.240.13d-7 for other
parties for whom copies are to be sent.
ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)
Exhibit A Item 7 Statement
As discussed in Item 4(a), certain shares reported herein are held
through Perceptive Life Sciences Master Fund Ltd., a Cayman Islands company, of
which Joseph Edelman is the managing member of the fund's investment manager.